News

Electronic health interventions improved medication adherence in kidney transplant recipients, with potential implications for improving patient outcomes.

Herzig outlined a talk she gave at the ACP Internal Medicine 2025 meeting reviewing the latest data in acute inpatient pain management.

Deepak Bhatt, MD, MPH, MBA, explores high-impact trials from ACC.25, including REVERSE-IT, Alpaca, ADVANCE-HTN, SOUL, STRIDE, and DapaTAVI.

In this interview, Chovatiya highlighted the unmet needs of patients with atopic dermatitis and the ways in which nemolizumab’s FDA approval addresses them.

In this episode, hosts break down the STRIDE and SOUL trials presented at the American College of Cardiology 2025 Annual Scientific Sessions.

Gelles discussed AI tools that are becoming a part of clinician’s armamentariums and the impact they are having on the field.

Study findings suggest significant socioeconomic disparities in preemptive kidney transplantation rates in children and the need for targeted interventions.

Investigators examined the safety of the recalled sickle cell disease medication through retrospective analysis of an FDA database.

Assigned a PDUFA target date of August 27, 2025, the resubmitted application for the wet AMD treatment will offer another chance for US approval.

Peter Lio, MD, discusses the value of hyperfocused meetings such as RAD and what sessions he is most looking forward to at RAD 2025.

Test your knowledge below on pooled data from the ARCADIA 1 and 2 trials and stay up to date with clinical advancements in atopic dermatitis.

An analysis of data from 2 PBC and PSC cohorts suggests fatigue is common, especially in females with PBC, and may be influenced by pruritus.

Our Q1 2025 recap for ophthalmology spotlights 5 regulatory updates, 5 key trial announcements, and two episodes of our flagship ophthalmology podcast.

Our Q1 2025 recap for pulmonology spotlights 5 regulatory updates, 5 key trial announcements, and top expert perspectives in pulmonology care. Read now:

In our Q1 recap for dermatology, we spotlight clinical trial data, recent updates, and advancements in therapeutic options.

Q1 2025 sleep updates include FDA rejecting pitolisant NDA for idiopathic hypersomnia, iptacopan improving PNH fatigue, and more.

AHNCI is at the forefront of sarcoma research, with recent contributions presented at the 2024 Musculoskeletal Tumor Society annual meeting.

Lung cancer is still the leading cause of cancer deaths, but effective screening and early detection can decrease a person’s chance of dying by 20%.

AHN is proud to offer three highly skilled chronic total occlusion operators at Allegheny General Hospital.

Scoping review results suggest AUD medications may improve hepatic outcomes in patients with ALD, but limited research exists on such an association.

The AHN Medicine Institute is launching a new Advanced Allergy and Asthma Clinic.

Robotic-assisted joint replacement surgery may improve outcomes and recovery.

Aflibercept 8 mg produced the same or better results compared to other anti-VEGFs while requiring fewer injections.

Complex PAD may be treated by minimally invasive percutaneous transmural arterial bypass (PTAB) using the DETOUR System by Endologix.

Our Q1 2025 recap for cardiology spotlights 6 regulatory updates, 5 key trial announcements, and top expert perspectives in cardiac care.

Goenawan discussed a meta-analysis he presented at the ACP Internal Medicine 2025 meeting.

BRIMOCHOL PF, a combination eye drop for presbyopia, achieved all primary and secondary endpoints in its most recent trial.

This research highlights the potential of a tripeptide as a topical emollient-based cream for patients with psoriasis.